Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 8/20 | 0.46 |
| ▸ | KCNK3 | O14649 | 4/20 | 0.45 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17328206 | 0.94 | ENPP2 (0.51) | ENPP2KCNK3PTGER4PTGDR2CYP2C9 | |
| SCHEMBL17317934 | 0.94 | ENPP2 (0.51) | ENPP2KCNK3PTGER4PTGDR2CYP2C9 | |
| SCHEMBL17317568 | 0.94 | ENPP2 (0.51) | ENPP2KCNK3PTGER4PTGDR2CYP2C9 | |
| SCHEMBL17317601 | 0.93 | ENPP2 (0.50) | ENPP2KCNK3PTGDR2 | |
| SCHEMBL17317759 | 0.93 | ENPP2 (0.50) | ENPP2KCNK3PTGDR2 | |
| SCHEMBL17328158 | 0.93 | ENPP2 (0.50) | ENPP2KCNK3PTGDR2 | |
| SCHEMBL17317896 | 0.93 | ENPP2 (0.48) | ENPP2KCNK3PTGER4 | |
| SCHEMBL17328071 | 0.93 | ENPP2 (0.48) | ENPP2KCNK3PTGER4 | |
| SCHEMBL17328096 | 0.93 | ENPP2 (0.51) | ENPP2KCNK3 | |
| SCHEMBL17317567 | 0.93 | ENPP2 (0.51) | ENPP2KCNK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10144732-B2 | ATX modulating agents | BIOGEN MA INC. (US) | 2018-12-04 | — | — | US | claimed |
| US-10144732-B2 | ATX modulating agents | BIOGEN MA INC. (US) | 2018-12-04 | — | — | US | disclosed |
| US-20170197960-A1 | ATX MODULATING AGENTS | BIOGEN MA INC. | 2017-07-13 | — | — | US | disclosed |
| US-20170197960-A1 | ATX MODULATING AGENTS | BIOGEN MA INC. | 2017-07-13 | — | — | US | disclosed |
| EP-3152206-A1 | ATX MODULATING AGENTS | Biogen MA Inc. (US) | 2017-04-12 | — | — | EP | disclosed |
| WO-2015188051-A1 | ATX MODULATING AGENTS | BIOGEN MA INC. (US) | 2015-12-10 | — | — | WO | disclosed |
| WO-2015188051-A1 | ATX MODULATING AGENTS | BIOGEN MA INC. (US) | 2015-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197960-A1 | ATX MODULATING AGENTS | ENPP2, ATXN10, ATXN2 | ENPP2 1/4885KCNK3 1825/4885PTGER4 1257/4885 |
| US-10144732-B2 | ATX modulating agents | ENPP2, ATXN10, ATXN2 | ENPP2 1/4885KCNK3 1825/4885PTGER4 1254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.